Clinical Trials
42 trialsImmunotherapy Using Tumor Infiltrating Lymphocytes for Patients With Metastatic Cancer
National Institutes of Health Clinical Center (CC)
OCTANE
University Health Network, Toronto
Bintrafusp Alfa (M7824) and PDS01ADC Alone and in Combination With Stereotactic Body Radiation Therapy (SBRT) in Adults With Metastatic Non-Prostate Genitourinary Malignancies
National Institutes of Health Clinical Center (CC)
A Multi-Center Natural History of Urothelial Cancer and Rare Genitourinary Tract Malignancies
National Institutes of Health Clinical Center (CC)
Testing the Effectiveness of Two Immunotherapy Drugs (Nivolumab and Ipilimumab) With One Anti-cancer Targeted Drug (Cabozantinib) for Rare Genitourinary Tumors
National Cancer Institute (NCI)
Administration of Autologous T-Cells Genetically Engineered to Express T-Cell Receptors Reactive Against Neoantigens in People With Metastatic Cancer
National Institutes of Health Clinical Center (CC)
Anti-tumour Activity of (177Lu) rhPSMA-10.1 Injection
Blue Earth Therapeutics Ltd
SHERLOCK
University Health Network, Toronto
EV-309
Astellas Pharma Inc
Low to Moderate Load Power Training for Men With Metastatic Prostate Cancer.
University of Alicante
Comparative Effectiveness Trial of Two Supportive Cancer Care Delivery Models for Adults With Cancer
Stanford University
P300
Pathos AI, Inc.
STOP-VTE
Wake Forest University Health Sciences
STRIKE-001
K36 Therapeutics, Inc.
Fecal Microbiota Transplantation in Treating Immune-Checkpoint Inhibitor Induced-Diarrhea or Colitis in Genitourinary Cancer Patients
M.D. Anderson Cancer Center
Feasibility Study of CBCT for IGRT in Cancer Patients
Varian, a Siemens Healthineers Company
Role of Gut Microbiome and Fecal Transplant on Medication-Induced GI Complications in Patients With Cancer
M.D. Anderson Cancer Center
Riluzole For Preventing Cognitive Dysfunction in Ca Pts Receiving Chemo (REFOCUS): Pilot Trial
University of California, Irvine
Circulating Tumor DNA (ctDNA) for Early Treatment Response Assessment of Solid Tumors
Washington University School of Medicine
SOGUG-PRINCIS
Spanish Oncology Genito-Urinary Group
OPTICS
DL Analytics
PROMES-URO
Centre Hospitalier Universitaire de Nīmes
Discharge Medication Use Post-Operatively in GU Cancer Patients
Wake Forest University Health Sciences
CD70-targeted immunoPET Imaging of Kidney Cancer
RenJi Hospital
PRIAM
The Netherlands Cancer Institute
Vorolanib in the Second-line Treatment of Patients With Unresectable or Metastatic Renal Cell Carcinoma
Jinling Hospital, China
ABACUS-2
Queen Mary University of London
Gender Related Coping and Survivorship for Genitourinary Cancers
Johns Hopkins University
CAPTIV-8
British Columbia Cancer Agency
TURANDORELA
The Netherlands Cancer Institute
PREMIER
RefleXion Medical
UroLymph
Universitaire Ziekenhuizen KU Leuven
PREVENT-GU
Ottawa Hospital Research Institute
START-001
Marengo Therapeutics, Inc.
Repurposing Riluzole for Cancer-Related Cognitive Impairment: A Pilot Trial
University of California, Irvine
uTRACT
UroGen Pharma Ltd.
High-resolution PET-CT Specimen Imaging for the Perioperative Visualization of Resection Margins
Algemeen Ziekenhuis Maria Middelares
GENIUS
University Health Network, Toronto
RCT_LiESWT
Regina Elena Cancer Institute
18F-Fluciclovine PET/CT Impact on Predicting Clinical Outcome of 177Lu-PSMA-617 Therapy in Patients With Prostate Cancer
VA Greater Los Angeles Healthcare System
A Study to Evaluate 9MW2821 Versus Treatment of Physician's Choice for Subjects With Recurrent or Metastatic Cervical Cancer
Mabwell (Shanghai) Bioscience Co., Ltd.
Pembrolizumab and Lenvatinib for Platinum- Sensitive Recurrent Ovarian Cancer
Sheba Medical Center